Menarini Group expanded its presence in Africa by opening a new headquarters in Cape Town in March 2024 and commenced full operations on January 1, 2025, after receiving registration certificates from the Healthcare Authority (SAHPRA), Department of Health (DOH), and the South African Pharmacy Council (SAPC). While the Florence-based pharmaceutical company has long collaborated with South African partners, this direct presence strengthens its foothold in one of Africa’s most significant pharmaceutical markets.
The team spearheads several initiatives to broaden the company’s product portfolio and bring new treatments to South African patients over the coming years. Regional Head of Africa Attilio Di Gaudio and Country Manager Nico Bosch shared their vision about the expansion.
The South African subsidiary will initially concentrate on cardiovascular, respiratory, and pain management therapies, with plans to branch into other therapeutic areas.
As part of the launch, the Menarini team is undergoing comprehensive training for their work with healthcare professionals, to ensure alignment with Menarini’s high standards.